SCHEMBL26977207

SCHEMBL26977207

CO[C@@H]1[C@@H](n2cc(-c3ccc(Cl)c(F)c3)nn2)[C@@H](O)[C@@H](CO)O[C@@H]1Cc1cc(C(C)(C)C)on1

nearest known ligand 0.59

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 20/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26977478 0.92 LGALS3 (0.57) LGALS3
SCHEMBL26977281 0.92 LGALS3 (0.58) LGALS3
SCHEMBL26977177 0.91 LGALS3 (0.54) LGALS3
SCHEMBL26977364 0.90 LGALS3 (0.55) LGALS3
SCHEMBL23041925 0.89 LGALS3 (0.52) LGALS3
SCHEMBL26977256 0.88 LGALS3 (0.54) LGALS3
SCHEMBL26977472 0.87 LGALS3 (0.49) LGALS3
SCHEMBL29672519 0.86 LGALS3 (0.57) LGALS3
SCHEMBL23041998 0.86 LGALS3 (0.57) LGALS3
SCHEMBL26977492 0.86 LGALS3 (0.57) LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319672-B2 Alpha-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-03 — — US claimed
EP-4021904-B1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2024-01-03 — — EP claimed
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2022-09-08 — — US claimed
CN-114585619-A alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-06-03 — — CN claimed
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2025-08-14 — — US disclosed
US-12319672-B2 Alpha-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-03 — — US disclosed
EP-4021904-B1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2024-01-03 — — EP disclosed
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2022-09-08 — — US disclosed
CN-114585619-A alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-06-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 LGALS3 2/4885
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 LGALS3 2/4885
US-12319672-B2 Alpha-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 LGALS3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback